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Abstract The purpose of making a ‘‘biobetter’’ biologic
is to improve on the salient characteristics of a known
biologic for which there is, minimally, clinical proof of
concept or, maximally, marketed product data. There
already are several examples in which second-generation
or biobetter biologics have been generated by improving
the pharmacokinetic properties of an innovative drug,
including Neulasta [a PEGylated, longer-half-life version
of Neupogen (filgrastim)] and Aranesp [a longer-half-
life version of Epogen (epoetin-a)]. This review describes
the use of protein fusion technologies such as Fc fusion
proteins, fusion to human serum albumin, fusion to car-
boxy-terminal peptide, and other polypeptide fusion
approaches to make biobetter drugs with more desirable
pharmacokinetic profiles.
Key Points
Biobetters are biologics based on an innovative
biologic but with improved properties.
Fusion proteins have been used in the
biopharmaceutical industry for over 25 years to
improve the pharmacokinetic properties of otherwise
short-half-life biologics.
Biobetter fusion proteins with longer half-lives or
with targeting moieties are being developed for
several innovative biologic drugs.
1 Introduction to Protein Pharmacokinetics
and Elimination
There are now more than 180 therapeutic proteins and
peptides approved by the US Food and Drug Administra-
tion (FDA) for a wide variety of indications, ranging from
alleviation of neuropathic pain to rheumatoid arthritis and
replacement enzymes for lysosomal storage diseases. Many
of these proteins and peptides have less than optimal
pharmacokinetic properties, often because they are smaller
than the kidney filtration cutoff of around 70 kDa [1, 2]
and/or are subject to metabolic turnover by peptidases,
which significantly limits their in vivo half-life [3]. An
example of this is the serum half-life of native glucagon-
like peptide (GLP)-1, which is about 1–2 min, primarily
because of peptidic cleavage by dipeptidyl peptidase
(DPP)-4 [4, 5]. Moreover, for virtually all of these proteins
and peptides, dosing is parenteral, so each dose is repre-
sented by either a subcutaneous or intravenous injection.
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High dosing frequency, a small area under the curve
(AUC), and patient inconvenience are limitations of short-
acting peptides. Thus, in many cases, second- or third-
generation modifications of those protein or peptide drugs,
intended to decrease their sensitivity to proteases [5] and
glomerular filtration by the kidney [1, 2], have been
developed to improve their pharmacokinetic profiles.
Pharmacokinetics is often described as what the body
does to the drug, whereas pharmacodynamics is described
as what the drug does to the body. The pharmacokinetics of
proteins and peptides is governed by the parameters of
absorption, biodistribution, metabolism, and elimination.
Absorption of peptides and proteins is generally via the
lymphatic system [6], biodistribution is generally limited to
the extracellular space in the central compartment (e.g.,
3–8 L [5]), the volume of distribution is generally\15 L,
metabolism occurs through enzymatic cleavage by pro-
teases and peptidases [3–5], and proteins and peptides are
eliminated from the serum by several different tissue- and
receptor-mediated mechanisms. The most common routes
of clearance for proteins and peptides include endocytosis
and membrane transport-mediated clearance by liver hep-
atocytes for larger proteins, and glomerular filtration by the
kidney for smaller proteins and peptides [1, 5].
While not all of the parameters involved in glomerular
filtration of peptides and proteins are fully understood yet,
it is clear that size, shape, hydrodynamic radius, and charge
all play significant roles [1, 2]. Generally, proteins and
peptides smaller than approximately 70 kDa are more
likely to be eliminated by kidney filtration than are larger
proteins [1, 2]. Additionally, charge plays a significant role
in glomerular filtration. Negatively charged peptides or
smaller proteins may be eliminated less readily than neutral
polypeptides because of repulsion by the negatively
charged basement membrane of the kidney [1, 7]. Cationic
polypeptides, on the other hand, tend to be removed even
more quickly [7]. Thus, two key strategies have been
employed to improve the pharmacokinetics of smaller
proteins and peptides, i.e., increasing the size and hydro-
dynamic radius of the protein or peptide, or increasing the
negative charge of the target protein or peptide. A third
strategy, similar to that employed with small molecules, is
to increase the level of serum protein binding of the peptide
or protein through binding to albumin [8, 9] or
immunoglobulins [10].
Traditionally, the typical modification made in the past
to improve the pharmacokinetics of peptide or biologic
drugs was via conjugation to either linear or branched-
chain monomethoxy poly-ethylene glycol (PEG), resulting
in increases in the molecular mass and hydrodynamic
radius, and a decrease in the rate of glomerular filtration by
the kidney [1, 2, 11, 12]. PEG is a highly flexible,
uncharged, mostly non-immunogenic, hydrophilic, non-
biodegradable molecule, which generates a larger hydro-
dynamic radius than an equivalently sized protein [1, 2].
PEGylation has been used widely as a means to lengthen
the half-life of proteins, e.g., PegIntron [PEGylated
interferon (IFN)-a2b] and Pegasys
 (PEGylated IFN-a2a)
for treatment of hepatitis B, Neulasta (a PEG-conjugated
granulocyte colony-stimulating factor [G-CSF] for treat-
ment of chemotherapy-induced neutropenia), and Mycera
(a PEGylated form of epoetin-b). While PEG has been
approved by the FDA as a GRAS (generally recognized as
safe) molecule [13], it has been associated with vac-
uolization of renal cortical tubular epithelium cells [14],
bringing its safety at least somewhat into question. Addi-
tionally, PEG is not metabolized by the body. Because of
safety concerns—as well as the high cost of PEG itself and
the need for chemical conjugation to the protein, followed
by repurification of the conjugate [15]—more and more
companies are seeking safer and less expensive alternatives
to PEGylation. Another approach that has been utilized to
improve pharmacokinetic parameters includes modification
of glycosylation patterns, resulting in reduced clearance
and extension of half-life. The best example of this
approach is Aranesp (darbepoetin-a), a second-generation
epoetin with modified glycosylation, which has a threefold
longer half-life than epoetin-a [16]. Table 1 provides a few
historical examples in which peptide or protein drugs have
been modified by non-fusion protein approaches to
improve either pharmacokinetics, biodistribution, or both.
In this review, protein fusion methods for improving the
pharmacokinetics of peptides and small proteins are dis-
cussed in some detail. The most widely used of these
approaches include fusion of the biologically active protein
or peptide to human serum albumin (HSA), fusion to the
constant fragment (Fc) domain of a human immunoglob-
ulin (Ig) G, or fusion to non-structured polypeptides such
as XTEN [17]. The intent here is to demonstrate both
examples and possibilities for generating improved bio-
logics, or ‘‘biobetters’’, from proteins or peptides that have
desired pharmacological properties but less than optimal
pharmacokinetic properties. Of 43 fusion proteins (FPs)
recently found in phase 2 or phase 3 clinical trial devel-
opment, 20 have been identified as being constructed
strictly for extension of half-life [18]. Protein fusion bio-
betters employing targeting approaches are touched upon
as well.
2 Definition of ‘‘Biobetter’’
Since the goal of the research described in this review is to
make ‘‘biobetter’’ molecules, it is critical to define what a
‘‘biobetter’’ is and to differentiate it from ‘‘biosimilar’’
(which is intended to be a close copy of the originator’s
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innovative drug [19]) and next-generation molecules (which
may have additional characteristics that separate it from the
original innovative molecule). The innovative molecule is
the first one to be developed and marketed. Examples of
innovative molecules pertinent to this discussion are Vic-
toza (liraglutide; modified, acylated GLP-1), Roferon-A
(IFN-a2a), Nutropin AQ
 [somatropin; human growth hor-
mone (hGH)], and Neupogen [filgrastim; recombinant
human G-CSF (rhG-CSF)]. A biobetter form of one of these
molecules would involve taking the originator molecule and
making specific alterations in it to improve its parameters
and thereby make it a more efficacious, less frequently
dosed, better targeted, and/or better tolerated drug. Thus, an
HSA fusion of hGH, which would give the pharmacologi-
cally active hGH a significantly longer serum half-life and
reduce dosing frequency, could be a ‘‘biobetter’’ version of
hGH. On the other hand, a novel peptide or protein binding to
the hGH receptor in a manner not necessarily exactly like the
binding of hGH would be classified as a next-generation
biologic [19]. An example of a potential next-generation
biologic is the monoclonal antibody CG-172, an hGH
receptor agonist that demonstrates signaling capabilities
somewhat different than those generated by hGH agonism of
the hGH receptor [20].
3 Major Types of Fusion Proteins
for Improvement in Pharmacokinetics
As mentioned above, many peptides and proteins have
half-life profiles that are not optimal for parenteral thera-
peutic dosing. To address this shortcoming, typically one
of six general strategies for prolongation of half-life has
been, or may be, used (Table 2):
1. Genetic fusion of the pharmacologically active peptide
or protein to a naturally long-half-life protein or
protein domain (e.g., Fc fusion [21–23], transferrin
[Tf] fusion [24], or albumin fusion [25, 26]).
2. Genetic fusion of the pharmacologically active peptide
or protein to an inert polypeptide, e.g., XTEN [17]
(also known as recombinant PEG or ‘‘rPEG’’), a homo-
amino acid polymer (HAP; HAPylation [27]), a
proline-alanine-serine polymer (PAS; PASylation
[28]), or an elastin-like peptide (ELP; ELPylation
[29, 30]).
3. Increasing the hydrodynamic radius by chemical
conjugation of the pharmacologically active peptide
or protein to repeat chemical moieties, e.g., to PEG
(PEGylation [1, 2, 11, 12]) or hyaluronic acid [31].
4. (a) Significantly increasing the negative charge of
fusing the pharmacologically active peptide or protein
by polysialylation [32]; or, alternatively, (b) fusing a
negatively charged, highly sialylated peptide (e.g.,
carboxy-terminal peptide [CTP; of chorionic gonado-
tropin (CG) b-chain] [33]), known to extend the half-
life of natural proteins such as human CG b-subunit, to
the biological drug candidate [34, 35].
5. Binding non-covalently, via attachment of a peptide or
protein-binding domain to the bioactive protein, to
normally long-half-life proteins such as HSA [8, 9],
human IgG [10], or possibly transferrin.
6. Chemical conjugation of peptides or small molecules
to long-half-life proteins such as human IgGs [36, 37],
Fc moieties [38], or HSA [39].
Only the peptide or protein genetic fusion approaches,
outlined above (1, 2, and 4b) and summarized in Table 2,
are described in this paper. There are several other recent












date of original approval
Neulasta
(PEG-filgrastim)
PEGylation Amgen (approved Jan 2002) Neupogen
(filgrastim)





Amgen (approved Sep 2001) Epogen
(epoetin-a)
Amgen (approved Jun 1989)
Plegridy
(PEG-IFN-b1a)
PEGylation Biogen Idec (approved Aug 2014) Avonex
(IFN-b1a)
Biogen (approved May 1996)
PegIntron
(PEG-IFN-a2b)












Hoffman-La Roche (approved Jun
1986)
Raw data were obtained from the US Food and Drug Administration website and assembled
IFN interferon, PEG poly-ethylene glycol
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reviews on this general topic [3, 11, 40–42] that can be
accessed for additional information.
4 Fusion of Pharmacologically Active Moiety
to Naturally Long-Half-Life Proteins
4.1 FcRn and its Effect on the Pharmacokinetics
of IgG Fc-Based and Albumin-Based Fusion
Proteins
The half-life of peptides and proteins in human serum is
dictated by several factors, including size, charge, prote-
olytic sensitivity, nature of their biology, turnover rate of
proteins they bind, and other factors [5]. In some cases, the
half-life of proteins in human serum can be roughly cor-
related with their size, as shown in Table 3. As mentioned
previously, peptides and proteins smaller than approxi-
mately 70 kDa can be eliminated via kidney filtration, so
they generally possess very short serum half-lives. Larger
proteins, however, may persist for several days. Three
types of proteins—human IgGs, HSA, and transferrin—
persist for much longer in human serum than would be
predicted just by their size (Table 3). The exaggerated
persistence of human IgGs and HSA has been determined
to be due to their binding to the neonatal Fc receptor (FcRn
[44, 45]), whereas the clathrin-dependent transferrin
receptor-elongated half-life of transferrin [49] is described
separately in Sect. 4.4.
FcRn is a heterodimeric receptor, closely related to
major histocompatibility complex (MHC) class I receptors
[45], which is widely expressed in vascular epithelial cells,
endothelial cells, intestinal epithelial cells, mammary
epithelial cells, placental membranes, monocytes, macro-
phages, dendritic cells, and polymorphonuclear (PMN)
leukocytes. FcRn contains a 45 kDa, transmembrane a-
chain with a short cytoplasmic tail, and a *17 kDa b-2
microglobulin b-chain [43–46]. While FcRn functions to
translocate IgGs from the mother to the fetus, it also has a
significant function in both IgG and HSA homeostasis.
Table 2 Examples of half-life-extension strategies employing polypeptide fusions to small proteins and peptides to generate biobetters
Strategy Specific
approach
Construct Mechanism for half-life
extension
Fusion to human protein with





Genetic fusion to C-terminus or N terminus of human




Fusion to HSA Genetic fusion to C-terminus or N terminus of HSA,






Genetic fusion to C terminus or N terminus of human





Fusion to non-structured polypeptide





Genetic fusion of non-exact repeat peptide sequence
(Amunix, Versartis) to therapeutic peptide
Increase in size and
hydrodynamic radius
[17]
PASylation Genetic fusion of polypeptide sequences composed of
PAS (XL-Protein GmbH) forms uncharged random coil
structures with large hydrodynamic volume
Increase in size and
hydrodynamic radius
[28]
ELPylation Genetic fusion to ELP repeat sequence (PhaseBio) can
extend half-life
Increase in size and
hydrodynamic radius
[29, 30, 50]
HAPylation HAP (e.g., homopolymer of glycine residues) Increase in size and
hydrodynamic radius
[27]
GLK fusion Fusion with artificial GLK Increase in size and
hydrodynamic radius
[51]
Fusion to highly anionic polypeptide
to increase negative charge
CTP fusion Genetic fusion of CTP peptide from human CG b-subunit
to antibody fragment (Prolor Biotech)
Increase in negative
charge via sialylation
of CTP [34, 35]
CG chorionic gonadotropin, CTP carboxy-terminal peptide, ELP elastin-like peptide, Fc constant fragment, FcRn neonatal Fc receptor,
GLK gelatin-like protein, HAP homo-amino acid polymer, HSA human serum albumin, Ig immunoglobulin, PAS proline-alanine-serine poly-
mer, rPEG recombinant poly-ethylene glycol, XTEN genetic fusion of non-exact repeat peptide sequence
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Upon pinocytosis of serum proteins by cells of the reticu-
loendothelial system, human IgG1, IgG2, and IgG4 isotypes
and HSA bind FcRn in a pH-dependent manner. As the
vesicles are acidified, the IgGs and HSA bind FcRn, which
allows them to be translocated back to the cell surface for
recycling back into the circulation, while non-FcRn-bound
proteins are targeted for lysosomal degradation. Upon
exposure to the neutral pH at the cell surface, the IgGs and
HSA are released back into the circulation [43, 44]. This
recycling mechanism confers a nominal 14- to 21-day half-
life on human IgG1, IgG2, and IgG4, and a *19-day half-
life on HSA [43–48]. Human IgA, IgM, IgD, and IgE do
not bind FcRn and do not possess an extended half-life, and
human IgG3 has an altered residue in the FcRn-binding
domain, which decreases its ability to bind FcRn, resulting
in a diminished half-life of *5–7.5 days [52]. The IgGs
bind to FcRn at a different epitope than HSA, so the
molecules do not compete [48]. Chaudhury et al. [47]
calculated that for every IgG molecule recycled by FcRn,
approximately 700 molecules of HSA are recycled. Thus,
FcRn plays a significant role in the homeostasis of both
human IgGs and HSA, the most abundant proteins in
human serum. These properties have been used many times
to improve the in vivo pharmacokinetics of otherwise
short-lived peptides and proteins, as documented in the
next few sections.
4.2 Fc Fusion to Make Biobetters
As mentioned above, human IgG isotypes 1, 2, and 4 bind
to FcRn in a pH-dependent manner to effect their recycling
by epithelial cells [43, 44]. This binding occurs via specific
residues in the Fc of the antibody, giving these IgG iso-
types a nominal 2- to 3-week half-life in human serum
[53]. The concept of using IgG Fc as a fusion partner to
significantly increase the half-life of a therapeutic peptide
or protein has been around since the late 1980s, when
Capon et al. [54] described the first Fc fusion protein
(which they called an ‘‘immunoadhesin’’), made by fusing
the Fc portion of IgG to the exodomain of cluster of dif-
ferentiation (CD)-4. Enbrel (etanercept), the first Fc
fusion protein to be marketed, was approved in 1998, and
many Fc fusion proteins have been described since [21–23,
53, 55].
Table 3 Nominal half-life






Ratio of half-life to molecular
mass
HSA 456 67 6.8
Transferrin 288 80 3.6
IgG1, IgG2, IgG4 480 146 3.3
IgG3 144 165 0.87




Factor H 87 155 0.56
Factor XIII 168 320 0.5
C-reactive protein 48 125 0.38
Factor IX 22 57 0.38
Fibrinogen 100 340 0.29
IFN-a 5 19 0.26
IgE 48 188 0.25
Pentameric IgM 144 970 0.15
IL-2 1.7 15 0.11
Thyroglobulin 65 660 0.1
G-CSF 2 20 0.1
Factor VIIa 3 50 0.06
PYY3–36 0.13 4 0.03
IGF-1 0.17 8 0.02
hGH 0.3 22 0.014
GLP-1 0.03 4 0.008
G-CSF granulocyte colony-stimulating factor, GLP glucagon-like peptide, hGH human growth hormone,
HSA human serum albumin, IFN interferon, Ig immunoglobulin, IGF insulin-like growth factor, IL in-
terleukin, PYY peptide tyrosine tyrosine
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Many Fc fusion proteins of various types have been
made over the past 35 years, virtually all of which were
intended to prolong the half-life of a protein or peptide. As
of May 2015, 11 Fc fusion proteins of various types had
been approved for marketing by the FDA (Table 4). Eight
of these were first-generation, innovative drugs, in which
the Fc moiety was fused to a protein or peptide to enhance
its pharmacokinetics (Table 4). On the other hand, three of
the more recent Fc fusion proteins—Eloctate, Alprolix,
and Trulicity—all approved by the FDA in 2014, are
‘‘biobetters’’ (Table 4), as described in the following sec-
tions. Strohl and Strohl [53] reviewed 27 different Fc
fusion proteins, most of them innovative, which are either
approved for marketing (e.g., Enbrel, Amevive, and
Orencia) or are in clinical trials. There are several other
recent reviews on Fc fusion proteins and peptides [21–23,
55–57]. Since the field of Fc fusions is so expansive, the
remainder of this section is devoted only to those Fc
fusions that are potential biobetter drugs in development.
4.2.1 The Examples of Eloctate and Alprolix
Syntonix Pharmaceuticals, acquired by Biogen Idec in 2007,
developed a technology for making monomeric Fc fusion
molecules, in which a therapeutic protein is attached to only
one arm of a dimeric Fc. The resultant protein is monovalent
for the pharmacologically active ‘‘head’’ moiety but retains
the normal bivalent Fc structure and function [58, 59]. Bio-
gen has used the monomeric protein-Fc technology to
develop a whole series of potential extended-half-life bio-
logics, including IFN-b-Fc, IFN-a-Fc, epoetin-Fc, B-do-
main-deleted Factor VIII-Fc, and Factor IX-Fc. Two of
these monomeric Fc fusion proteins were approved by the
FDA in 2014: Alprolix (eftrenonacog-a; monomeric Fac-
tor IX-Fc of approximately 98 kDa) and Eloctate
(efraloctocog-a; monomeric B-domain-deleted Factor VIII-
Fc of approximately 220 kDa) (Table 4).
In clinical trials, Factor IX-Fc (Alprolix) was shown to
have a terminal half-life in the range of 57–83 h, which
was about threefold longer than the half-life of *18 h
obtained with other formulations of Factor IX alone [60,
61]. This is comparable to the clinical trial data on the half-
life of 89–96 h for recombinant Factor IX (rFIX)-FP, an
rFIX-HSA fusion protein in phase 3 clinical development
by CSL Behring [62, 63]. For Factor VIII (Eloctate), the
Fc fusion improved the half-life by only about 50 % from a
range of *12 h for historical Factor VIII preparations to
about 19 h for Factor VIII-Fc [64].
4.2.2 The Example of Trulicity (Dulaglutide)
Pharmacologically active peptides, which typically have
sequences of 40–50 amino acids or shorter, typically have
very short half-lives in human serum (Table 3), often
because of both enzymatic inactivation and glomerular fil-
tration by the kidney. These peptides include peptide tyr-
osine tyrosine (PYY), neuropeptide Y (NPY), GLP-1, GLP-
2, oxyntomodulin, pancreatic polypeptide, gastrin, and oth-
ers [65, 66]. Thus far, of these various incretins, only the
GLP-1 pathway has been converted from the laboratory into
a drug. Natural GLP-1 has a half-life in serum of about 2 min
(Table 3), so in its native form, it could never be a drug.
Three peptide-based drugs—Byetta/Bydureon (exe-
natide), Victoza/Saxenda (liraglutide), and Lyxumia
(lixisenatide)—are GLP-1 receptor agonists (Table 5).
Liraglutide, which is an acylated form of DPP-4-resistant
GLP-1 (containing GLP-1 amino acid residues 7–37), has a
half-life in human serum of about 13 h. Exenatide and
lixisenatide are exendin-4 analogs; exendin-4 is a DPP-4-
resistant peptide, originally isolated from the saliva of the
Gila monster lizard (Heloderma suspectum), which pos-
sesses both a structure and activity highly similar to human
GLP-1 [67]. Exenatide is the synthetic form of exendin-4
used in these drugs. These peptides have half-lives of a few
hours in human serum (Table 5).
A GLP-1-Fc fusion protein designed and developed by
Eli Lilly possesses the activity of GLP-1 with a serum half-
life of 4–5 days, which supports once weekly dosing
(Table 5). This Fc fusion protein contains a DPP-4-resis-
tant version of GLP-1 (V8-GLP-1) fused to the Fc of a
human IgG4 (F234A/L235A) via a linker [68]. The length
and structure of the linker was found to be a critical
component of the design, because in the absence of the
linker, the GLP-1 agonist activity was minimal [68]. The
Eli Lilly GLP-1 Fc fusion protein, marketed under the
name Trulicity (dulaglutide), was approved by the FDA
in September 2014 (Table 4). A similar GLP-1 Fc (IgG4-
ala-ala) fusion protein, known as the GLP-1-Mimeti-
bodyTM construct, CNTO530 [76], was also designed and
taken into phase 2 clinical trials by Centocor, but it was
later dropped. Similarly, a GLP-1 fusion with the Fc of an
IgG2 was recently published [77]. A critical point for all
three of these constructs is that the Fc moieties were
designed for minimal Fc activity, as opposed to using the
Fc of an IgG1, which could result in effector function
activity and potentially killing activity toward the target
cells possessing the GLP-1 receptor (GLP-1R). The
importance of the silent or muted Fc has been discussed in
further detail by Strohl and Strohl [53].
There are four examples shown in Table 6 of potential
biobetter Fc or IgG fusion protein candidates. An inter-
leukin (IL)-2-anti-GD-2 antibody fusion currently in
phase 2 clinical development by researchers at the National
Cancer Institute is a potential biobetter of Proleukin by
virtue of the anti-GD-2 targeting. Similarly, the IL-2 fusion
protein with an anti-tenascin C single-chain variable
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fragment (scFv), in phase 1/2 clinical trials by Philogen, is
a biobetter because of targeting rather than half-life
extension. Two other programs in the preclinical space
include the recombinant Factor VIIa-Fc fusion [78] being
developed by Biogen Idec and Swedish Orphan Biovitrum
(SOBI), and a recombinant von Willebrand factor domains
D0 and D3-Fc fusion [79] for treatment of patients with
hemophilia A. In this last case, if the novel fusion molecule
were developed, it would replace a plasma-derived
product.
4.3 Albumin Fusion
The 66.5 kDa protein HSA, similar to human IgGs, has a
long average half-life in the 19-day range (Table 3). At a
concentration of *50 mg/mL (*600 lM), HSA is the
most abundant protein in human plasma, where it has
several functions, including maintenance of plasma pH,
metabolite and fatty acid transport, and a role in main-
taining blood pressure. HSA, which is at the upper limit of
size for glomerular filtration of proteins by the kidney, is
strongly anionic, which helps even more to retard its fil-
tration via the kidney [1]. Like IgGs, HSA also binds FcRn
in a pH-dependent manner [47], albeit at a site different
from—and via a mechanism distinct from—that of IgG
binding [48], and is recycled similarly to IgGs, resulting in
its extended half-life [44, 48]. HSA also tends to accu-
mulate in tumors and in inflamed tissues, which suggests
that fusion or binding to albumin may potentially help to
target proteins or peptides to those sites [89].
The fusion of peptides or proteins with inherently short-
half-life properties to HSA for prolongation of the serum
half-life has been investigated broadly since the early
1990s, after Yeh et al. [90] published a paper documenting
the 140-fold improvement in half-life of a CD4 exodo-
main-HSA fusion over that of CD4 exodomain alone. The
biotechnology company Principia Pharmaceuticals was
spun out with the intellectual property for HSA fusion
protein technology in the late 1990s from Aventis Behring,
the forerunner to today’s CSL Behring. Shortly afterwards,
Principia was acquired by Human Genome Sciences in
September 2000 [91]. Since then, dozens of different
peptides and small proteins have been fused to HSA as
both innovative and potential biobetter molecules, as
reviewed by several authors [25, 26, 89, 92–96]. Compa-
nies leading the way with HSA fusion technology include
GlaxoSmithKline (which obtained rights when they
acquired Human Genome Sciences in 2012), Teva (which
obtained rights upon acquisition of the HGS spin-off),
Cogenesis, and CSL Behring.
The first HSA-peptide or protein fusion product to be
approved for marketing is Tanzeum (marketed as
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1-HSA fusion protein discovered at Human Genome Sci-
ences and developed and marketed by GlaxoSmithKline.
Tanzeum (albiglutide), which was approved by the
European Medicines Agency (EMA) and the FDA in
March and April 2014, respectively (Table 4), improves
the half-life of pharmacologically active GLP-1 from
1–2 min for native GLP-1 (Tables 3, 5) to 4–7 days, which
allows for once weekly dosing (Table 5). Tanzeum is a
biobetter version of the first generation of GLP-1 receptor
agonists such as liraglutide. It is a direct competitor with
dulaglutide, described above, for the once weekly dosing
T2DM market. As shown in Table 6, there are at least eight
additional preclinical or discovery-stage fusion proteins
with either GLP-1, exendin-4, or the dual GLP-1R/gluca-
gon receptor agonist, oxyntomodulin, that could potentially
be biobetters of liraglutide.
Table 6 lists seven other known HSA fusion protein
product candidates that are either now in development or
recently have been in development. The most advanced of
these is CSL654 (also known as rFIX-FP [97]), which has
completed phase 3 clinical trials. CSL Behring, which is
developing CSL654, submitted a Biologics License
Application (BLA) to the FDA in December 2014. If
approved for marketing, CSL654 will become a biobetter
version of Baxter’s Rixubis, an rhFactor IX, which was
just recently approved by the FDA in 2013. CSL654 (rFIX-
FP) demonstrated a terminal half-life in humans of 89–96 h
[62, 63], which compared very favorably with the half-life
of the FIX-Fc fusion protein, Alprolix, which had a ter-
minal half-life of 57–83 h [60].
Another significant HSA fusion protein in clinical
studies is hGH-HSA fusion. This fusion protein, once
known as Albutropin [98], was developed preclinically by
Human Genome Sciences but is now being developed
clinically by Teva, which acquired the asset when it
acquired the HGS spin-off company Cogenesis in 2008.
TV-1106, formerly called Albutropin, is now in phase 2
clinical trials (Table 6).
Not all HSA fusions have fared well in clinical trials. The
development of two different forms of G-CSF-HSA fusions,
EgranliTM (also known as balugrastim and NeugraninTM)
and albugranin, has been halted. EgranliTM was taken into
late-stage clinical development by Teva and submitted to
both the EMA and FDA for marketing, but the applications
were recently withdrawn (Table 6). A third G-CSF-HSA
fusion protein, sponsored by Jiangsu T-MAb Biopharma
Co., Ltd., is still in phase 1 clinical development. Similarly,
an IFN-a2b-HSA fusion protein [99] known as albuferon
(also known as JoulferonTM and ZalbinTM) was under
development by Human Genome Sciences and Novartis for
treatment of patients with hepatitis C [100]. Albuferon was
discontinued from development in 2010 because of its
questionable safety profile.
A very interesting bispecific antibody-HSA fusion pro-
tein, MM-111, is currently in phase 2 clinical development
by Merrimack. The protein is a fusion of an anti-Her3
(ErbB3) scFv antibody-HSA-anti-Her2 (ErbB2) scFv
(Table 6), which is being developed for the treatment of
breast, esophageal, gastric, and other Her2-positive can-
cers. The HSA confers on the scFvs (which normally have
a half-life as free scFvs of\1 h [53]) a half-life of 86–90 h
[101]. If this protein is eventually approved for marketing,
it may be a biobetter version of Genentech’s Herceptin,
which was first approved for marketing in 1998. In this
case, the biobetter property would not be half-life extension
but, rather, the addition of the second antibody, anti-Her3,
which gives it added activity, especially in cancers
expressing high levels of heregulin [102].
Two other HSA fusion biobetter proteins are currently
known to be in clinical development (Table 6): IFN-a2a-
HSA fusion (sponsored by Beijing Bio-Fortune Ltd.),
which is in phase 1/2 trials, and CSL689 (rFVIIa-FP), a
Factor VIIa-HSA fusion protein for treatment of hemo-
philia A or B patients with bleeding episodes. The IFN-
a2a-HSA fusion protein would be a longer-half-life bio-
better candidate for Roche’s Roferon-A, while CSL689
would be a longer-half-life biobetter competitor for Novo
Nordisk’s NovoSeven (Table 6). Finally, other HSA
fusion proteins have been mentioned in the literature,
including an IL-2-HSA fusion protein and a b-natriuretic
peptide-HSA fusion protein, both of which were in devel-
opment in the past but have apparently been discontinued.
Novozymes, a protein engineering company in Den-
mark, has been developing modified versions of recombi-
nant HSA with improved FcRn binding for construction of
‘‘next-generation’’ HSA-protein fusions that may possess
even longer half-life properties. A K573P mutant of HSA,
which was found to possess 12-fold greater affinity for
FcRn, conferred a longer half-life on HSA than wild type in
both mice and cynomolgus monkeys [103]. The expecta-
tion is to use these longer-half-life mutants of HSA as
fusion proteins to improve the half-life of fusion proteins
even further.
4.4 Transferrin Fusion
Transferrin is a highly abundant serum glycoprotein, found
in serum at 3–4 mg/mL, which binds iron tightly but
reversibly and functions to carry iron to tissues. Transferrin
has 679 amino acid residues, is about 80 kDa in size, and
possesses two high-affinity Fe3?-binding sites, one in the
N-terminal domain and the other in the C-terminal domain
[104]. Human transferrin has a half-life reported to be
7–10 days [86] or 10–12 days [11]. The aglycosylated
form of human transferrin, which makes up about 2–8 % of
the total transferrin pool, has a slightly longer half-life of
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14–17 days [86]. The extended persistence of transferrin in
human serum is due to a clathrin-dependent transferrin
receptor-mediated mechanism, which recycles transferrin
receptor-bound transferrin back into the circulation [49,
105].
Fusions of peptide and proteins have been made to human
transferrin to the N- and C- termini, as well as to the centrally
located hinge region that links the two major lobes of
transferrin together. The N terminus of transferrin is free and
can be fused directly. The C terminus is more buried and is
constrained by a nearby disulfide bond, so flexible linkers are
typically used when proteins are fused to the C terminus.
This capability was extended by making libraries of peptides
against specific targets and then fusing binders from those
libraries into aglyco-transferrin (N-terminal, C-terminal,
loops, or linker region) to be developed into therapeutic
fusion proteins with extended half-lives [106].
The biotechnology company BioRexis Technologies,
Inc., was founded in 2002 to develop the transferrin fusion
protein platform, which they termed the ‘‘Trans Body’’
platform, as a therapeutic platform. Their lead molecule,
BRX-0585, was a transferrin-GLP-1 fusion protein for
treatment of type 2 diabetes mellitus (T2DM). Fusion of
GLP-1 to transferrin was demonstrated to significantly
enhance the half-life of GLP-1. BioRexis was acquired by
Pfizer in March 2007. As far as can be determined, no
BioRexis-derived fusion proteins are currently in the clinic.
Bai et al. [107] reported the construction of a human
G-CSF-transferrin fusion protein with oral bioavailability
in mice. When the G-CSF-Tf fusion protein was adminis-
tered orally, pharmacodynamic activity was observed for
3 days, as compared with only a single day of pharmaco-
dynamic effects after subcutaneous injection.
A few recent reports have suggested that transferrin
fusion is still being considered for biobetters, as summa-
rized in Table 6. Kim et al. [86] generated fusions of GLP-
1 and exendin-4 to a non-glycosylated form of human
transferrin to produce longer-half-life versions of those
metabolism-related peptides. Both molecules retained most
of the activity of the native peptides while providing sig-
nificant improvements in half-life. Matsubara et al. [108]
also fused a DPP-4-resistant analog of GLP-1 to non-gly-
cosylated transferrin and used the longer-half-life molecule
to improve outcomes in myocardial ischemia/reperfusion
models. This molecule improved the half-life of GLP-1 in
rabbits from a few minutes to 27 h [108]. Very recently, an
exendin-4-transferrin fusion was generated and produced in
plants [85]. This plant-produced form of exendin-4-trans-
ferrin fusion was found to have some level of oral
bioavailability, suggesting some promise as an orally
delivered therapy [85].
Recently, a proinsulin-transferrin fusion prodrug was
generated, which underwent a cleavage to bioactive insulin
in hepatic cell culture in a transferrin receptor manner [87,
109]. The hypothesis for this activity was that transferrin
receptor-mediated endocytosis resulted in intracellular
cleavage of the proinsulin to the active insulin-transferrin
fusion. In vivo studies, interestingly, demonstrated insulin
activity of the insulin-transferrin fusion in liver but not
skeletal muscle [87].
5 CTP Fusion: Half-Life Extension Through
Charge
Another interesting peptide fusion approach has a very
different mechanism of action. Thyroid-stimulating hor-
mone (TSH; also known as thyrotropin) and the three
gonadotropins, follicle-stimulating hormone (FSH),
luteinizing hormone (LH), and CG, are heterodimeric
glycohormones consisting of a common a-subunit and
unique b-subunits, which confer on them their different
activities [110]. The half-life of human CG (HCG) is sig-
nificantly longer than that of its counterparts, FSH, LH, and
TSH. The difference between HCG and its counterparts is
that the HCG b-subunit (HCG-b) possesses a *31-amino-
acid-residue CTP consisting of the sequence FQSSSS*
KAPPPS*LPSPS*RLPGPS*DTPILPQ, which possesses
four O-glycosylation sites (denoted by S*) terminating with
a sialic acid residue [111]. CTP has been demonstrated to
naturally extend that protein’s half-life in human serum,
likely because the negatively charged, heavily sialylated
CTP impairs renal clearance [34].
The CTP technology was developed for potential com-
mercial use by Prolor Biotech, Inc., which was acquired by
OPKO in August 2013. Over the past decade or so, CTP
has been fused to several hormones, factors, and cytokines
in an attempt to elongate their half-lives. CTP was genet-
ically fused to the C-terminus of erythropoietin (EPO),
resulting in a recombinant EPO-CTP that demonstrated a
substantially improved half-life and improved in vivo
potency over normal EPO [112].
FSH-CTP (corifollitropin-a, Org 36286) was the first CTP
fusion to be taken into clinical trials as a long-acting FSH for
treatment of infertility in women [33, 113]. FSH-CTP con-
sistently demonstrated about a twofold improvement in half-
life over recombinant FSH, no matter whether it was dosed
subcutaneously or intravenously [33, 112]. The FSH-CTP
fusion protein (Org 36286) was approved by the EMA in
February 2010 as a long-acting fertility drug named Elonva
(corifollitropin-a [114]), marketed by Merck and Co. Elon-
va has not been approved by the FDA.
Besides Elonva, at least three other CTP fusion pro-
teins are in clinical trials (Table 6). CTP has also been
genetically fused with hGH to make a long-acting hGH-
CTP chimera (LagovaTM; MOD-4023), which had a
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substantially extended half-life and a greater AUC than
hGH alone in rat models [115]. This translated into a
12-fold improvement in serum half-life in humans [116], as
compared with a *3.4-h half-life for recombinant hGH
dosed subcutaneously in humans [117]. OPKO partnered
LagovaTM (MOD-4023; hGH-CTP) with Pfizer in
December 2014 for continued development and potential
commercialization. LagovaTM is currently in phase 3
clinical trials for treatment of pediatric growth hormone
deficiency (Table 6).
Additionally, a coagulation Factor IX-CTP fusion protein
has been reported by OPKO to be in phase 1 clinical trials for
treatment of hemophilia B, and a coagulation Factor VIIa-
CTP fusion protein is in preclinical studies at OPKO for
treatment of bleeding episodes with hemophilia A or B
(Table 6). Investigational New Drug (IND) applications
have been filed with the FDA to initiate phase 2a clinical
trials for both the Factor IX-CTP and Factor VIIa-CTP
fusion proteins, and the Factor VIIa-CTP fusion protein has
been granted an Orphan Drug Designation by the FDA.
Overall, it appears that fusion of CTP to a protein is
likely to extend its half-life by two- to fourfold and perhaps
more in isolated cases. Fusion of CTP to peptides appears
to elongate their half-lives even more, although the pub-
lished data are less well developed for this use. One sig-
nificant limitation of this technology is that the
recombinant CTP fusion must be produced in Chinese
hamster ovary (CHO) or other mammalian cell systems, so
that the resultant recombinant proteins are O-glycosylated
in the CTP extension module [35]. Whether CTP fusion to
any particular peptide or small protein target will prove to
significantly enhance its half-life is yet to be determined.
Nevertheless, in a situation in which modest half-life
extension is desired, along with a product that is negatively
charged (because of the multiple sialylations), CTP fusions
might be a valid approach.
OPKO/Prolor have generated other CTP fusions, includ-
ing an IFN-b-CTP (MOD-9023), which they claimed in a
press release to have 55-fold greater overall exposure over
IFN-b alone, as well as a CTP fusion with the anti-obesity
peptide oxyntomodulin (Table 6), with claims of 100-fold
more durability than the naturally occurring peptide. The
status of those programs is unknown. Separately, JW Phar-
maceutical Corporation constructed an IFN-a-CTP fusion
for use in antiviral indications [84], but nothing more is
known about the current development of this protein.
Finally, in an effort to build a better vaccine, Tang et al.
[118] generated a novel fusion of the hepatitis B virus (HBV)
core 18–27 peptide (HBcAg18–27), which primes HLA-
class I restricted immune responses in patients acutely
infected with HBV, with CTP and the endoplasmic reticulum
chaperone tapasin to make the fusion HBcAg18–27-tapasin-
CTP. This construct, which strongly activated CD8?
T cells, was tested as a potential innovative target-specific
immunogen for HBV vaccine design [118].
6 Recombinant Polypeptide Chains
While the use of PEG to increase the hydrodynamic radius
of peptides or small proteins to increase their half-life in
human serum remains a significant and clinically tested
approach [1, 2, 12], several new strategies have emerged as
an alternative to chemical conjugation to PEG or other non-
biologic polymers. The common thread for all of these
strategies is the fusion of inert peptide repeat polymers to
the recombinant protein to be modulated. This approach
might be viewed as a hybrid of the PEG conjugation
approach and fusion to the naturally long-half-life proteins
IgG Fc, albumin, or transferrin. This polypeptide fusion
approach yields four immediate advantages over PEGyla-
tion: (1) the cost of the PEG moiety and the time and
process cost for the chemistry to couple it to the protein are
eliminated; (2) the entire construct can be made in a
‘‘single pot reaction’’ in Escherichia coli for many peptides
and small proteins; (3) only a single round of purification is
required rather than purification followed by conjugation
and then repurification, as occurs with PEGylated proteins
[15]; and (4) the peptides, while largely extracellular pro-
tease resistant, will be slowly degraded by natural pro-
cesses in vivo. The two major potential drawbacks of these
platforms are the potential for immunogenicity of the
polypeptide repeat units and unknown factors, as compared
with the much better-studied Fc and HSA fusions.
6.1 XTEN
In developing the Versabody scaffold, scientists at Amunix
investigated the ability of an amino acid repeating polymer
to extend the half-life of various versabodies and other
small proteins. They generated a library of sequences
containing the amino acid residues A, E, G, P, S, and T,
and scored for expression in E. coli, followed by analysis
for genetic stability, solubility, lack of aggregation, and
heat stability [17]. From these data, several sequences,
dubbed ‘‘XTEN’’ sequences, were tested for their ability to
extend the half-lives of peptides such as exenatide and
glucagon, and proteins such as green fluorescent protein
(GFP) and hGH. XTEN lengths of 288 (*32 kDa) to 1008
(*111 kDa) residues were tested in mouse, rat, and
monkey models, resulting in half-life improvements rang-
ing from 50- to 125-fold for the peptides in different animal
models and up to *12-fold for GFP [17]. Rabbit tests with
GFP-XTEN demonstrated an immune response to the GFP
but little or none to the XTEN moiety. In those experi-
ments, the XTEN moiety also appeared to possess some
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level of shielding effect, similar to PEG. Recently, Gee-
thing et al. [82] tested glucagon fused with XTEN moieties
ranging from 36 to 288 amino acid residues in length. The
XTEN sequences ranged from inexact repeats of …
GSEGEG … and similar sequences to much more highly
randomized sequences containing longer inexact repeats of
residues similar to … AESPGPGTSPSGESSTAPGT …
[82]. They tested the pharmacodynamics of these con-
structs in fasted dogs and demonstrated that they could
prevent hypoglycemia without inducing temporary hyper-
glycemia, an event often associated with glucagon alone.
The sequence of their most optimized glucagon-XTEN
compound designed to treat nocturnal hypoglycemia con-
tained 144 amino acid residues fused to the C-terminus of
glucagon [82].
There are currently nine known XTEN fusion programs that
appear to be intended as biobetter programs (Table 6). The
furthest along in development is VRS-317, which is a fusion of
hGH and XTEN [119]. VRS-317, currently being developed by
Versartis, is in phase 3 clinical trials (Table 6). VRS-317 was
demonstrated to possess a 131-h half-life in humans [120],
which is considerably longer than that of recombinant, sub-
cutaneously dosed hGH [117] and much longer than that of the
CTP-hGH fusion protein, MOD-4023 [116].
The only other XTEN fusion molecule currently in the
clinic is VRS-859 (Table 5), a fusion of XTEN and exen-
din [17], which is currently in phase 1 clinical trials for
glycemic control in patients with T2DM. Fusion of XTEN
to exendin increased the half-life in rats and mice from 65-
to 71-fold, and in monkeys from about 30 min to 60 h [17].
Additional Amunix preclinical XTEN biobetter pro-
grams, listed in Table 6, include gcg-XTEN (glucagon-
XTEN fusion [82]), IL-1ra-XTEN, and the coagulation
factors rFVIIa-XTEN, rFVIII-XTEN, and rFIX-XTEN.
Amunix partnered the rFVIII-XTEN program with Biogen
Idec in April 2014, and partnered with Eli Lilly in
December, 2014, for assets in the T2DM field. Amunix has
also recently partnered two programs with Naia Limited,
including NB1001 (GLP-1-XTEN) and NB1002 (AMX-
256; GLP-2-2G-XTEN [83]), the latter of which is an
XTEN-peptide fusion. Other XTEN fusion proteins have
been reported previously, including AMX-213 (a ghrelin-
XTEN fusion protein), AMX-888 (a C-peptide-XTEN
fusion), and AMX-583 (an a-1-anti-trypsin-XTEN fusion
protein) [121], but no information is available on these
candidates currently, suggesting that they may not be in
active development.
6.2 ELPylation
A second method for half-life extension of peptides and
proteins via polypeptide fusion is the use of ELPs, which are
repeating peptide units containing sequences commonly
found in elastin, for ‘‘ELPylation’’. The ELP sequence
contains repeats of V-P-G-x-G, where x is any amino acid
except proline [29, 30]. The fact that this sequence can be
degraded over time by human elastases makes ELP polymers
biologically degradable. ELPylation is a process by which
ELP repeat sequences are genetically fused to a target protein
to enhance a thermally responsive phase transition [29, 30].
Thus, at higher temperatures, above the so-called transition
temperature, ELPs aggregate and fall out of solution. When
the temperature is decreased below the transition point, they
become fully soluble again. Modification of the ‘‘x’’ posi-
tion, i.e., making it more or less polar or charged, alters the
transition state of the polymer. This property has been
exploited for protein purification and as a scaffold platform
for tissue growth. It has also been demonstrated that fusion of
ELP sequences to small therapeutic proteins enhances the
half-life of those proteins by giving them a larger hydrody-
namic radius and thus they are not eliminated by the kidney
[50]. An anti-tumor necrosis factor (TNF)-a VHH (single-
domain) antibody of about 12 kDa was fused with ELP,
resulting in a substantially increased half-life of the VHH
protein in rodent models [50].
The biotechnology company PhaseBio (http://phasebio.
com) is developing ELPylation as an aid in protein
purification and as a half-life-extension module for inno-
vative and biobetter product candidates. PhaseBio currently
has three ELPylated products in clinical trials: (1) Gly-
meraTM (PB1023), an ELPylated, 636-amino-acid-long
fusion with GLP-1, which is intended for once weekly
dosing as a biobetter form of Victoza [75] (Tables 5, 6)
and is currently in phase 2 clinical trials (Table 6);
(2) PE0139, an ELPylated form of insulin, which is
intended to be a long-acting, biobetter form of Humulin
and other short-acting insulin products, and is currently in
phase 1 clinical trials (Table 6); and (3) VasomeraTM
(PB1046), an ELPylated fusion of vasoactive intestinal
peptide (VIP; a naturally occurring 28-amino-acid peptide),
which appears to be an innovative drug candidate and is a
selective VPAC2 receptor agonist, being developed as a
weekly dosed treatment of cardiopulmonary diseases.
Recent evidence, however, has demonstrated that super-
agonism of VPAC2 in mice is correlated with a significant
risk of development of neurological disorders [122], sug-
gesting caution in this approach.
6.3 PASylation
Another approach to using polypeptide repeat sequences is
PASylation, which comes from the generation of a polymer
using three repeating amino acids, proline, alanine and
serine (i.e., PAS). PAS polymers of 100–200 repeats in
length were shown to improve the pharmacokinetics of
small proteins in mice by 3.5- to 6-fold over non-
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PASylated proteins [28]. A fusion of a 600-residue PAS
polypeptide with a type I IFN, the product of which was
called YNSa8, was demonstrated to possess both a tenfold
longer half-life and pharmacodynamic activity in trans-
genic mice than IFN itself [123]. Arne Skerra (of Tech-
nische Universita¨t Mu¨nchen) founded a biotech company,
XL-Protein GmbH (http://www.xl-protein.com), to com-
mercialize the use of PASylation to improve the half-lives
of peptides and small proteins [124]. Currently, XL-Protein
GmbH has 15 preclinical programs listed on their website,
six of which appear to be intended as extended-half-life
biobetter forms of existing peptides and short protein
products (Table 6).
6.4 Other Polypeptide Fusion Approaches
Another approach for utilizing polypeptide chains to
extend the half-life of peptides or proteins is ‘‘HAPylation’’
(Table 2), e.g., use of a glycine-rich HAP genetic fusion to
increase half-life [27]. Inert repeat sequences similar or
identical to (Gly4Ser)n have been used for many years as
linker sequences to link subunits, single chains, and pep-
tides together [125].
Schlapschy et al. [27] investigated the use of HAPyla-
tion to increase the hydrodynamic radius of an anti-HER2
Fab 4D5 to extend the Fab’s half-life in animal models.
They fused 100 and 200 residues of a repetitive sequence
(Gly4Ser)n to its light chain and showed that the 200 resi-
due ‘‘HAPylated’’ Fab had a hydrodynamic volume more
than double that of the Fab alone, resulting in a moderate
increase in half-life. It does not appear that this technology
has been developed further.
Finally, a gelatin-like protein (GLK) polymer was fused
to G-CSF to generate a long-half-life derivative [51]. The
GLK-G-CSF fusion protein retained the same activity as
recombinant G-CSF on a molar basis, indicating that the
fusion did not affect activity, as so often occurs with
fusions and conjugates. Additionally, the half-life in rats
was increased from 1.76 h (rG-CSF) to about 10 h (rGLK-
G-CSF), similar to the values obtained with Neulasta
(PEG conjugate; Table 1) and AlbugraninTM (albumin
fusion; Table 6).
7 Comparison of the Various Fusion Protein
Formats
Table 7 shows a comparison of the various half-life-ex-
tension platforms described in this paper. The most widely
used, best understood, and most ‘‘conservative’’ constructs
are Fc fusion proteins. This platform was first described in
the late 1980s [54], and in the form of etanercept (En-
brel), it has been manufactured for human use since 1998.
Fc fusion has become so common that it is widely used to
generate reagent proteins for assays and experiments, and
Fc fusions of receptor exodomains and other proteins are
widely available commercially as test reagents. Addition-
ally, ten Fc fusion proteins have now been approved in
major markets for medical use (Table 4). This widespread
knowledge has a potential downside from the patentability
side (see Sect. 8.6), as it is usually now considered obvious
to make an Fc fusion protein to lengthen the half-life of
receptor exodomains and cytokines [125]. Of the other
fusion protein partners, HSA fusion proteins have now
been pretty well characterized [18] and are represented by
one marketed product (Table 4) and at least another eight
clinical candidates (Table 6). Additionally, the use of CTP
as a fusion partner to extend the half-lives of proteins has
been well characterized, with one marketed product
(Table 4) and three more clinical candidates. Beyond those
examples, however, the overall knowledge about fusion
partners, such as ELP, XTEN, PAS, HAP, and others,
becomes much thinner, and the safety, efficacy, potential
immunogenicity, and manufacturing profiles of these lesser
studied fusion proteins are more difficult to assess
(Table 7). It does appear, however, that VRS-317 (XTEN-
hGH) [119] and GlymeraTM (ELP-GLP-1) [75], both cur-
rently in phase 2, may have properties (e.g., activity, effi-
cacy, pharmacokinetics, lack of high immunogenicity) that
are solid enough to take into late-stage development, which
will more definitively test their characteristics as potential
drugs. The other platforms (e.g., PASylation, HAPylation,
GLK-fusion) are too early in development for us to know
yet whether they can stand the test of clinical and scale-up
manufacturing development.
8 Potential Issues with Biobetter Fusion Proteins
Fusion proteins made with Fc, HSA, CTP, XTEN, or other
fusion partners described in this review are novel mole-
cules not found in nature. They are instead constructed of
two or more parts of proteins found in nature and are often
fused together genetically via unnatural amino acid linkers.
In some cases, the half-life-extension fusion partner is not
natural, such as XTEN, HAP, GLK, PAS, or ELP, all of
which utilize repeat units of amino acids. These types of
unnatural proteins, even though they are constructed at
least in part with natural components, can raise a series of
potential manufacturing and dosing challenges, including
developability, stability, solubility, immunogenicity, and
loss of activity in comparison with the native protein.
During development of these novel extended-half-life
protein fusions, these and other factors need to be taken
into careful consideration to reduce unwanted side effects
or unstable products.
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8.1 Half-Life Improvements
The mean and median half-life values for approved thera-
peutic antibodies are about 12–13 days, about a week shy
of the oft-quoted textbook values of approximately 21 days
[53]. Nevertheless, most of the Fc fusion proteins generated
to date have half-life values in humans of about 4–5 days
(Table 7). The notable exception is abatacept, which has a
half-life of about 13–16 days [129]. Belatacept, which has
a structure that differs from abatacept by only two amino
acid residues, has an average half-life of about 8–9 days
[130]. The shorter-half-life values for Fc fusion proteins
may be due to lower affinity to FcRn or the higher-order
structure provided by Fab arms of normal antibodies [131].
Additionally, the protein or peptide ‘‘head groups’’ of Fc
fusion proteins are likely the targets of proteinases that
increase their turnover. Similarly, even though serum
albumin has a half-life in humans of about 19 days, the
half-life of albiglutide is only about 5 days. Thus far, other
fusion partners tested in the clinic, such as CTP, ELP, or
XTEN, have done no better, with the fusion proteins pos-
sessing half-life values of 2.5, 4–5, and 4–5 days, respec-
tively (Table 7). Thus, with the possible exceptions of
abatacept and the structurally related belatacept, the half-
life values of fusion proteins are typically less than 5 days,
which would be on the low side for a typical therapeutic








Half-life potential Immunogenicity potential Potential issues
Fc fusion 1989 [54] Approved for
commercial
use
Proven; half-life range from
4 days (etanercept) to
*16 days (abatacept) in
humans
Modest in those Fc fusions
currently marketed;
potential for neo-epitopes
in linker fusion region
Stability, aberrant
glycosylations in linkers and
fusion proteins; Fc
functionality or lack thereof
HSA fusion 1992 [90] Approved for
commercial
use
Proven; about 5 days in
humans
Modest in those HSA fusions
currently marketed;
potential for neo-epitopes
in linker fusion region
Biodistribution may be more
limited
CTP fusion 1992 [34] Approved for
commercial
use
Proven, albeit modest (*3-
day half-life is typical in
humans)
Very low incidence (0.16 %)




negative charge may impact
biological activity for some
fusions
XTEN fusion 2009 [17] Clinical
phase 3
Proven; about 4–5 days in
humans [120]
About 10 % low-level, non-
neutralizing ADAs in VRS-
317 phase 1 study
Many unknowns
ELPylation 1992 [126] Clinical
phase 2
Approximately 3 days in
phase 1 study of
GlymeraTM
\4 % in phase 1 study of







2004 [127] Preclinical Unknown for humans Unknown Many unknowns
PASylation 2008 [128] Preclinical Unknown for humans; 2–3
days in mice,
approximately 8- to
tenfold over native protein
Unknown, but unlikely to be
due to simple repeating
sequence of PAS residues
Many unknowns
HAPylation 2007 [27] Preclinical Unknown for humans; only
*6-h half-life in mice
Unknown for humans Seemingly short-half-life
improvement; many
unknowns
GLK fusion 2010 [51] Discovery Unknown for humans; about










ADA anti-drug antibody, CTP carboxy-terminal peptide, ELP elastin-like peptide, Fc constant fragment, GLK gelatin-like protein, HAP homo-
amino acid polymer, HSA human serum albumin, PAS proline-alanine-serine polymer, XTEN genetic fusion of non-exact repeat peptide
sequence
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monoclonal antibody [53]. For most of these fusion pro-
teins, the best dosing schedule to be expected would be
weekly, with some potentially requiring two doses per
week. While this is far better than the native peptides or
proteins alone, it is still far more frequent dosing than that
of most therapeutic antibodies [53].
8.2 Activity of Protein Fusions: Importance
of Protein Engineering for Activity
The in vitro biological activity of fusion proteins, as
measured by the half-maximal inhibitory concentration
(IC50) or the half-maximal effective concentration (EC50),
is often lower than that of the original biologic that has
been fused to a protein to elongate its pharmacokinetic
profile [132–134]. These losses in activity may be due to
the decrease in the on-rate due to the bulkiness of the
fusion protein as compared with the original bioactive
protein, or, alternatively, steric hindrance. It has been
demonstrated that the linker type, length, and flexibility, as
well as fusion of the bioactive peptide or protein to the C or
N terminus of the half-life-extension module, can have
profound effects on the activity of the fusion proteins.
Examples follow for this phenomenon, and also for how
protein engineering in some cases can overcome this loss
of activity.
One example of this was demonstrated by Peng et al.
[133], who compared the in vitro activity, pharmacoki-
netics, and in vivo activity on somatostatin receptors
(SSTRs) 1–5 of native protein somatostatin-14 (SST14)
with a somatostatin-14 fusion (two 14-amino-acid copies of
SST14 fused to HSA; SST142-HSA). Fusion of HSA to
somatostatin-14 resulted in a 2.5-fold loss of activity for
SSTR4 and an approximate 15-fold loss of activity for
SSTR5, as measured by EC50 binding values for the vari-
ous SSTRs [133]. Interestingly, the HSA fusion affected
binding to the SSTRs differentially, resulting in different
ratios, which could potentially result in modified in vivo
functionality and/or toxicity profiles. Additionally,
SST142-HSA induced significantly lower levels of phos-
phorylation of the SSTR2 and SSTR3 downstream sig-
naling enzyme, ERK1/2, than did native SST14 [133], as
well as increasing the EC50 for cyclic adenosine
monophosphate (cAMP) accumulation by more than a log.
Finally, the HSA fusion inhibited SST receptor turnover as
compared with that of native SST14 [133]. Peng et al.
[133] did not try to engineer the linkers between the SST
and HSA in attempts to try to improve activity, so it is
unknown if the loss of activity might have been recovered
with further protein engineering.
In another example, linker engineering was used to
regain activity lost upon fusion of IFN-a2b to HSA [134]. A
direct fusion of IFN-a2b to HSA resulted in an unstable
protein with very little biological activity [134]. Zhao et al.
tested the effects of different linkers on the activity of IFN-
a2b in a fusion format. Peptide linkers are known to have an
influence on the expression, activity, and pharmacokinetics
of fusion proteins [132, 135]. Peptide linkers typically
come in either flexible forms (e.g., (G4S)n, where
n = 1–4) or in structurally more rigid forms, such as the a-
helical linker [A(EAAAK)nA]x (where n = 2–4 and x = 1
or 2), and XPn (where X is either A, K or E) [132, 135].
The advantage of flexible linkers is that the flexibility may
be required to obtain proper orientation of the bioactive
portion of the molecule with respect to its cognate receptor,
whereas flexible linkers do not give a lot of space between
the fusion partner and the bioactive protein [132, 135].
Rigid linkers, on the other hand, provide more space but
lack the flexibility [132, 135]. In the case of the IFN-a2b-
HSA fusion protein, the flexible linker resulted in
approximately 39 % activity as compared with that of
native IFN-a2b, whereas the rigid XP linker and the a-
helical linker resulted in 68 and 115 % of the activity of
native IFN-a2b, respectively [134]. Additionally, the fusion
proteins were demonstrated to possess good stability and
solubility. In another example, G-CSF was fused to trans-
ferrin, using a variety of different linkers. The use of a
short leucine-glutamate (LE) linker resulted in only
approximately 10 % of the activity of native G-CSF,
whereas insertion of either a (G4S)3 or a-helical
[A(EAAAK)nA]m (n = 2–4, m = 1 or 2) linker signifi-
cantly increased the activity of the fusion proteins over that
of G-CSF-LE-Tf. The fusion protein constructed with the
linker (A(EAAAK)4ALEA-(EAAAK)4A) resulted in bio-
logical activity near to that of native G-CSF, with the
added advantage of a long half-life in vivo [136]. These
studies demonstrate the importance of testing linker tech-
nology for the success of fusion protein programs.
Using a different approach, Ding et al. [137] demon-
strated the importance of fusion position for activity. The
fused brain natriuretic peptide (BNP) to either the N or C
terminus of HSA in several formats. The results showed
that BNP-HSA, BNP2-HSA (two copies of BNP), and
BNP4-HSA, all fused to the N terminus of HSA, were
devoid of significant biological activity, whereas HSA-
BNP2, fused to the C-terminus of HSA, was nearly as
active as native BNP, plus it had the advantage of a sig-
nificantly longer half-life [137].
These examples and many more like them in the liter-
ature demonstrate the importance of having a significant
effort in lead optimization of fusion proteins to optimize
the activity either through linker engineering, the position
of the bioactive protein or peptide with respect to the half-
life-extension module, or both.
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8.3 Developability and Stability Issues
One of the key issues facing the construction of novel
molecules is the potential for aggregation, particularly at
high concentrations, which are desired for formulations for
subcutaneous delivery. During the development of the
vascular endothelial growth factor (VEGF)-trap, which is
now commercially available as Eylea for treatment of
age-related macular degeneration (AMD), and Zaltrap,
which is available for treatment of metastatic colon cancer,
the first construct, which consisted of the first three
domains of VEGF receptor-1 (VEGFR1) fused to the
human IgG1 Fc region, was highly potent but had poor
pharmacokinetics and possessed non-specific binding
interactions, which made it unsuitable as a clinical candi-
date. Further engineering of the molecule was required to
result in the clinical candidate, which possesses better
pharmacokinetics, affinity, stability, and specificity [138].
Finally, aggregation, poor solubility, and lack of sta-
bility are key factors that can lead to heightened
immunogenicity, which can lead to increased clearance of
the drug, or, at worst, can generate an immune response
that also binds and clears the native protein [53].
8.4 Immunogenicity and Safety
One of the most critical issues for any protein therapeutic is
immunogenicity [139, 140]. Proteins contain both B cell
and T cell epitopes, which can be recognized by the
immune system as either self or foreign. B cell epitopes are
conformational epitopes found on the surface of the pro-
teins and are relatively difficult to assess preclinically.
T cell epitopes, on the other hand, are small linear pep-
tides, which are processed and presented by MHC to
T cells. Because of the extensive structural/functional
characterization of MHC-peptide complexes, many T cell
epitopes are known or can be predicted. Several computer
algorithms have been devised to test for the presence of
human T cell epitopes in proteins. Since non-human ani-
mal models clearly are not predictive of immunogenicity in
humans, the ability to test for immunogenicity preclinically
is limited. For most therapeutic proteins, efforts are made
to ‘‘de-immunize’’ the protein by eliminating as many
T cell epitopes as possible, using in silico T cell epitope
recognition programs and/or in vitro T cell assays [139].
Additionally, it has been suggested that addition of regu-
latory T cell epitopes, called ‘‘Tregitopes’’, may decrease
the immunogenicity of the fusion protein [139].
For most antibodies, significant immunogenicity results
in elimination of the antibody from the serum, so the most
significant issue is one of efficacy or lack thereof [53]. That
said, the incidence of immunogenicity for most humanized
and human antibodies is quite low, e.g., less than 10 %,
with most anti-drug responses being non-neutralizing [53].
For therapeutic proteins or fusion proteins containing a
native protein domain, however, immunogenicity of the
therapeutic product could potentially result in an immune
response against the native protein, which could potentially
exacerbate the disease for which the patient is being treated
[141]. Immunogenicity of fusion proteins may arise from
the fusion sites (which may form neo-epitopes not recog-
nized as self by the immune system), from allotypic
responses to proteins containing allogeneic sequences, by
improper formulation or packaging (which might lead to
the presence of an adjuvant that helps to drive an immune
response against the delivered protein [141]), or from
aggregation of the product (which could help drive the
immune response). Thus, optimization of the primary
sequence to reduce B or T cell epitopes [139] is only part
of the equation. Formulation, chemical and structural sta-
bility, lack of aggregation, solubility, and route of admin-
istration are also key factors to consider to minimize
immunogenicity of fusion proteins [53, 139, 140].
Thus far, Fc fusion proteins have been shown to have an
overall low incidence of immunogenicity as reported in the
package inserts for the products: etanercept has an inci-
dence of about 6 %, with the anti-drug response generally
being non-neutralizing [142]; fewer than 2 % of patients
treated with abatacept developed antibodies against the
drug, and while some of these were found to be neutral-
izing, there appeared to be little effect on clearance [129];
for belatacept, which is a modified version of abatacept,
about 8 % of patients generated an anti-drug response, but
clearance was not substantially affected [130]; about 1.6 %
of patients treated with dulaglutide generated anti-drug
antibodies, and about half of those were found to be neu-
tralizing. The one Fc fusion protein for which high anti-
drug antibody titers were reported was rilonacept, to which
35 % of patients who were tested generated an anti-drug
response [143]. It was reported, however, that these
responses were not associated with exaggerated clearance
or loss of activity of the drug.
For other types of fusion proteins, only low incidence
rates of anti-drug responses have been reported thus far.
For example, for the CTP fusion protein Elonva, fewer
than 0.2 % of patients generated anti-drug responses; for
the ELP fusion protein GlymeraTM, less than 4 %
immunogenicity was observed, and for the HSA fusion
protein Tanzeum, about 5 % of patients generated non-
neutralizing low-level anti-drug antibodies, which were not
correlated with clearance or loss of activity.
While these data are promising thus far, the potential for
immunogenicity that could result in antibodies against the
native proteins of protein fusions is still an important
consideration, which must be followed very carefully
during the development of these kinds of drugs. One word
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of caution in all of these reports is that the immunogenicity
assays used across the industry vary widely with respect to
sensitivity and specificity, so it is difficult to compare data
accurately across drugs or platforms [139].
8.5 Ancillary Activities
In generating Fc fusions, the activity of the Fc, which can
bind to Fcc receptors on several types of immune cells,
needs to be taken into consideration [53, 140, 144]. This
has been handled in different ways. For etanercept, the
IgG1 Fc was left intact but, because of the structure, this
resulted in overall lesser Fc functionality than what is
observed with an IgG1 antibody [145]. It has been postu-
lated that this lowered Fc activity may have resulted in
poorer efficacy in intestinal bowel diseases, where the Fc
activity may be important for binding cell surface-associ-
ated TNF-a [145]. For abatacept, the Fc and hinge region
were modified to reduce effector function [146].
8.6 Obviousness
One of the major problems today with the use of fusion
proteins such as Fc, IgG, or albumin to generate a biobetter
by extending the half-life of a biologically active, com-
mercially available peptide or protein (e.g., G-CSF, hGH,
etc.) is that it is now an obvious approach to take. This
obviousness has made it much more difficult to obtain
patent protection for constructs of these types [125]. There
are some examples in which obviousness may be obviated,
i.e., if the bioactive protein has been modified to possess
new or different activities from the original, or if making a
dimer using Fc or both ends of HSA significantly increases
activity or changes the biodistribution in a way that confers
novel biology or efficacy.
9 Summary
It is clear that biobetter drugs are here to stay. This review
has documented six marketed biobetter drugs generated via
protein fusion technologies, four of which (Alprolix,
Tanzeum, Eloctate, Trulicity) were approved for
marketing in just the past year (2014). Another 15 biobetter
clinical-stage candidate drugs and 23 preclinical-stage
candidates generated by protein fusion technologies have
also been discussed. The technologies most used thus far
have been albumin fusion and Fc fusion technologies, with
XTEN fusion, ELP fusion, and CTP fusion technologies
making significant advances over the past few years.
Within a few years, XTEN and ELP will likely join HSA,
Fc, and CTP as fusion partners represented by a marketed
biobetter drug. This, along with other biobetter fusion
proteins reaching approval in the next few years, will give
us a better view of which half-life-extension fusion tech-
nologies are best suited for which purposes (e.g., peptide
versus protein fusions).
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